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Abstract 
 
The 23-valent pneumococcal polysaccharide vaccine (PPV23) given alone is ineffective in patients 
with chronic lymphocytic leukemia (CLL) and better antibody response is achieved with 
pneumococcal conjugate vaccines (PCVs). In this study we determine whether CLL patients would 
achieve a significant antibody response and broaden their serotype coverage against invasive 
pneumococcal disease (IPD) with PPV23 given five years after the 7-valent conjugate vaccine 
(PCV7). A total of 24 patients with CLL and eight controls were vaccinated with PPV23 five years 
after PCV7. Blood samples for evaluation of antibody response to PCV7 serotypes and PPV23 
serotypes 5 and 7 were taken before vaccination and one month after it. Post-vaccination samples 
were available from 20 patients. IgG antibodies were measured with ELISA. Antibody 
concentrations after PPV23 were significantly lower in CLL patients for six of the PCV7 serotypes 
and for both PPV23 serotypes. Only 10 to 15% of CLL patients achieved an antibody response 
suggested to be protective against IPD. Hence, PCV7 given five years before PPV23 did not 
improve antibody response in patients with CLL. Based on our results, PPV23 given after a PCV 
primer is not useful against IPD in CLL patients. 
 
Keywords: chronic lymphocytic leukemia; pneumococcal polysaccharide vaccine; pneumococcal 
conjugate vaccine; booster vaccination; antibody response 
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Introduction 
 
Infections are the most important cause of mortality in patients with chronic lymphocytic leukemia 
(CLL), the most common type of leukemia in adult Caucasians. The usual bacterial pathogens 
responsible for respiratory tract and urinary tract infections are Streptococcus pneumoniae, 
Haemophilus influenzae, and Escherichia coli.1-2 CLL is associated with impaired immune system 
function even at an early stage of the disease.3 Both the specific and innate immunity are affected, 
leading to immunosuppression in patients with CLL.4 Abnormalities in specific (adaptive) 
immunity includes B- and T-cell dysfunction while disorders of complement system and neutrophil 
functions represent abnormalities in innate immunity.1,4,5-6 While hypogammaglobulinemia can 
occur at an early stage of CLL, it is usually more severe in the advanced stages of the disease.7 Low 
levels of IgG have been observed to correlate with severity of bacterial infections, morbidity, and 
mortality.8 
 
In contrast to pneumococcal polysaccharide vaccine (PPV), the T-cell dependent pneumococcal 
conjugate vaccines (PCVs) have been shown to induce higher avidity antibodies and immunologic 
memory and to create herd immunity.9 Antibody responses to pneumococcal vaccines in CLL 
patients are limited. Most studies with 23-valent PPV (PPV23) have shown no significant antibody 
responses.10-13 PCVs, in contrast, have proved immunogenic in CLL patients with limited response 
in a few earlier studies. In almost 40% of CLL patients, a response, that was considered significant 
was achieved after one dose of 7-valent PCV (PCV7) given at an early stage of the disease.14 
Furthermore, 13-valent PCV (PCV13) resulted in at least a two-fold increase in antibody titers from 
the baseline in 58% of untreated CLL patients, compared with 100% for healthy controls.15 In a 
recent randomized study PCV13 was compared to PPV23 in untreated CLL patients. Functional 
antibody titers measured by opsonophagocytic assay (OPA) were significantly higher for 11 out of 
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13 serotypes with PCV13 at one month after vaccination and for 6 out of 13 serotypes at six months 
after vaccination compared to PPV23. All antibody responses for PPV23 were inferior than 
achieved with PCV13.16 
 
PPV23 given after PCV may have a booster effect on antibody responses and may also broaden 
serotype coverage to PPV23 serotypes in immunocompromised patients. Patients with previously 
treated Hodgkin lymphoma achieved higher antibody concentrations for six serotypes contained in 
both vaccines when PPV23 was given one year after PCV7 in contrast to PPV23 alone.17 In stem 
cell transplant (SCT) recipients, the antibody response rates to pneumococcal serotypes 1 and 5 not 
included in PCV7 were 83% after one dose of PPV23 at 12 months and 89% 18 months after 3 
doses of PCV7 with the cut-off of ≥0.15 μg/ml set for response.18 Furthermore, 42% of allogeneic 
SCT recipients, who did not show a response after three doses of PCV7 achieved an antibody 
response of ≥0.15 μg/ml to the PCV7 antigens after a single dose of PPV23.19 
 
In this study we investigated the effect of a single dose of PPV23 given five years after PCV7 to 
evaluate whether CLL patients could obtain a boost to their antibody response and broaden their 
serotype coverage against invasive pneumococcal disease (IPD) with PPV23 primed with PCV7. 
 
Patients and methods 
 
The study population comprised 24 patients with CLL (12 males and 12 females), with a median 
age of 64 years (range 47-86 years) from Tampere and Turku University Hospitals. The control 
population comprised eight subjects (median age 67 years, range 57-82 years, four males and four 
females) without any known immunological or hematological defects from Tampere University 
Hospital. The patients and control subjects had participated in an earlier pneumococcal conjugate 
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vaccine response study with PCV7 containing capsular polysaccharides (PSs) of pneumococcal 
serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, and in an antibody persistence study.14,20 
 
An informed consent to participate was obtained from all patients and controls. The study was 
approved by the ethical board of the Pirkanmaa Hospital District and it was conducted in 
accordance with the Declaration of Helsinki. The trial was registered at http://ClinicalTrials.gov 
(NCT00919321). 
 
The study objectives were to compare antibody concentrations for PCV7 antigens and PPV23 
antigens 5 and 7F, as an example for antigens which are not included in PCV7, at one month after 
vaccination in CLL patients and controls with serotype-specific IgG antibodies as measured by 
ELISA and to determine the proportions of CLL patients achieving a significant serotype-specific 
antibody response against IPD after PPV23. 
 
The vaccine used was the 23-valent pneumococcal polysaccharide vaccine (Pneumovax®, MSD), 
which contains capsular PSs of pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F. A dose of 0.5 ml contains 25 µg of each PS 
type and phenol as an adjuvant. 
 
Patients and controls received one intramuscular deltoid injection with Pneumovax five years after 
PCV7. Venous blood samples for antibody analyses were taken before vaccination and one month 
after it. Serum was separated by centrifugation and stored at -20°C. The concentrations of serum 
IgG antibody against pneumococcal capsular PSs were measured at the National Institute for Health 
and Welfare (THL) by a modification of the 22F inhibition enzyme immunoassay (EIA) method as 
previously described.21 Additionally, venous blood samples were drawn from CLL patients for the 
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analysis of total blood count and immunoglobulins at the time of vaccination. These were analyzed 
at a local hospital. 
 
Antibody concentrations and proportionate changes between groups were compared by 
independent-samples Mann-Whitney test and the significance of antibody responses within groups 
by 2-tailed Fisher´s exact test. The values in the tables are expressed as geometric mean 
concentrations (GMC) and quartiles. An antibody concentration of 0.35 μg/ml was considered as a 
threshold for protection against IPD, as recommended by the World Health Organization WHO.22 A 
significant antibody response was defined as an at least two-fold increase from the baseline and a 
post-vaccination level of at least 0.35 µg/ml consistent with earlier PCV7 study.14 
 
Results 
 
Among the 24 CLL patients and eight controls enrolled in the study, post-vaccination samples were 
unavailable in the case of four patients. Therefore, the final study population comprised 20 CLL 
patients and eight controls (Table 1). No vaccine-related adverse events were reported. The disease 
status according to Binet classification was A (early stage of the disease) in 12, B (intermediate) in 
two, and C (advanced stage) in six patients. A total of 13 patients had never been treated for CLL. 
After administration of PCV7, six patients had received chemoimmunotherapy or chemotherapy, 
one patient CD52 monoclonal antibody (alemtuzumab) after chemotherapy and one patient had 
received allogeneic stem cell transplantation. Hypogammaglobulinemia (S-IgG <6.77 g/l) was 
detected in nine (45%) patients. Five patients had suffered from severe infections (needing 
intravenous antibiotics or hospitalization) and five patients from mild to moderate infections 
(treated with oral antibiotics) during the five years since PCV7 vaccination. Only one of these 
infections was invasive pneumococcal disease. 
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Antibody concentrations after PPV23 were significantly higher in controls for four of PCV7 
antigens (4, 9V, 14, 18C) and for both PPV23 antigens (Table 2). In contrast, no difference was 
observed in antibody concentrations for PCV7 antigens 6B, 19F and 23F. Before PPV23, i.e. five 
years after PCV7, no statistically significant differences were seen in antibody concentrations 
between patients with CLL and controls.20 
 
After PPV23, only 10 to 15% of CLL patients achieved a significant response to PCV7 antigens 
defined as an at least two-fold increase and a post-vaccination concentration of at least 0.35 µg/ml 
(Table 3). Among CLL patients, the responders were the same four patients depending on the 
serotype and they had never been treated for CLL. These patients were also among the PCV7 
responders. For PPV23 antigens 5 and 7, the corresponding percentages for CLL patients were 20% 
and 15%, respectively. Despite of poor antibody response, 30-75% of CLL patients remained their 
antibody concentrations at a level ≥0.35 µg/ml suggested to be protective against IPD depending on 
serotype. In controls, 75-88% achieved a significant response to PCV7 antigens 4, 6B, 9V, 14, 18C, 
19F. In contrast, the corresponding rate for serotype 23F was only 50%. For PPV23 antigens, all 
controls achieved a significant response. 
 
Discussion 
 
According to a few earlier studies, patients with Hodgkin´s lymphoma and SCT recipients benefit 
from a PCV primer before PPV23.17-19 Furthermore, in HIV-infected adults, PPV23 given one year 
after PCV13 improved PCV13 immunogenicity but in contrast had a negative effect on 
immunological memory induced by PCV13 by reducing the amounts of memory B-cells.23 Similar 
findings have been reported where PPV23 given after PCV depletes immunological memory. 
Longer intervals between pneumococcal vaccinations diminish this hyporesponsiveness and are 
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beneficial for immunogenicity.24 Our study was designed based on a long interval between 
vaccinations consistent with an updated recommendation.25 However, we did not observe this 
booster effect in CLL patients. Furthermore, a majority of the untreated CLL patients did not 
achieve an antibody response considered as significant for PPV23. Hence, in our data CLL therapy 
after PCV7 did not seem to have an influence on poor antibody responses for PPV23.  
 
An antibody concentration of 1.3 µg/ml is recommended as cut-off for protective antibody level 
against IPD in primary immunodeficiencies.26 This higher cut-off level may also be extrapolated to 
acquired immunodeficiencies, such as CLL related immune dysfunction. In our data, all responders 
in CLL group achieved this higher antibody concentration expect two out of four CLL patients for 
antibody 5. 
 
This is the first study to evaluate the effect of the 23-valent polysaccharide vaccine after the 
conjugate vaccine (PCV7) in patients with CLL. Although ≥50% of CLL patients remained their 
antibody concentrations at a protective level for 7 out of 9 serotypes, most of the CLL patients did 
not achieve an antibody response considered to be significant, as compared to controls. These data 
suggest that PCV is not capable of inducing memory B-cells in CLL patients, although our earlier 
data showed antibody persistence at least five years after PCV7, depending on the serotype.20 One 
probable reason for a poor antibody response with PPV23 after the PCV primer is abnormalities in 
both B- and T –cell functions even at an early stage of CLL, leading to inadequate immunogenicity 
of conjugate vaccines.1,4,15 Stage of the disease in our data did not impair antibody responses as 
most of the patients were Binet A patients. 
 
Our study has some limitations. The sample size remained small due to the natural course of CLL 
and the five-year interval between vaccinations. PCV7 has also been replaced with PCV13, but both 
 10 
have the same carrier protein, CRM.9 Furthermore, PCV13 has also been shown to generate 
suboptimal responses in CLL patients.15-16 Hence, our data should reflect immune responses to both 
PCV7 and PCV13.  
 
A PPV23 booster dose given five years after PCV7 seemed to be ineffective in inducing an 
antibody response suggested to be protective against IPD in CLL patients. Based on these data, 
PPV23 may not be useful as a part of the vaccination program after PCVs in patients with CLL. 
Future studies with the PCV13 primer are warranted in order to verify our data. Furthermore, 
whether CLL patients would benefit from a PCV13 booster instead of PPV23 needs to be studied. 
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Table 1. Clinical and laboratory characteristics of the patients with CLL. 
Character Patients with CLL (n=20) 
Sex M/F 11/9 
Age (years) 63 (47-86) 
Binet A/B/C 12/2/6 
Past CLL therapy 7 (35%) 
Lymphocyte count (x109/l) 21.9 (0.9-140.0) 
Platelet count (x109/l) 141 (38-372) 
Hemoglobin (g/l) 135 (81-153) 
Neutrophil count (x109/l 4.0 (0.6-12.1) 
IgG (g/l) 7.4 (3.2-12.5) 
The values are expressed as medians and ranges. 
 
 
 
 
Table 2. Pre- and post-vaccination antibody concentrations to seven serotypes included in the 7-
valent pneumococcal conjugate vaccine (PCV7, bold) and two serotypes included in the 23-valent 
pneumococcal polysaccharide vaccine (PPV23) in patients with CLL and in controls. 
 
Serotype Pre-vaccination antibody 
concentration GMC (μg/ml) 
(quartiles) 
Post-vaccination antibody 
concentration GMC (μg/ml) 
(quartiles) 
p-valuea 
CLL (n=20) Control (n=8) CLL (n=20) Control (n=8) 
4 0.12 (0.02-0.40) 0.34 (0.13-0.90) 0.13 (0.02-0.67) 1.96 (1.36-2.82) <0.001 
5 0.16 (0.08-0.44) 0.15 (0.08-0.25) 0.22 (0.08-0.64) 2.20 (0.53-5.57) 0.002 
6B 0.46 (0.11-1.69) 0.30 (0.06-1.24 0.56 (0.14-3.39) 2.28 (0.75-9.96) 0.063 
7F 0.38 (0.07-1.27) 0.56 (0.31-1.23) 0.55 (0.07-1.83) 6.74 (2.97-13.8) <0.001 
9V 0.51 (0.23-2.33) 0.91 (0.17-5.06) 0.62 (0.32-2.29) 3.04 (0.58-12.1) 0.033 
14 0.77 (0.20-4.14) 1.56 (0.45-5.83) 0.96 (0.17-6.20) 6.65 (3.00-24.0) 0.021 
18C 0.93 (0.26-3.06) 1.55 (1.00-2.47) 1.06 (0.27-4.07) 6.81 (3.82-15.7) 0.010 
19F 0.97 (0.30-2.88) 0.83 (0.31-1.56) 1.29 (0.33-4.20) 4.18 (1.88-6.05) 0.055 
23F 0.53 (0.14-1.56) 0.82 (0.25-2.23 0.67 (0.13-4.41) 2.29 (2.07-3.32) 0.150 
aBetween post-vaccination concentrations in patients with CLL and controls 
aIndependent-samples Mann-Whitney U-test (statistical significance if p ≤ .05) 
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Table 3. Significant response rates and post-vaccination antibody concentrations suggestive of 
protection (≥0.35 μg/ml) to seven serotypes included in PCV7 (bold) and two serotypes included in 
PPV23 in patients with CLL and controls. 
 Response ratea  Post-vaccination concentration 
≥0.35 μg/ml 
 CLL  Controls  CLL  Controls 
Serotype n=20 (%)  n=8 (%) p-valueb n=20 (%)  n=8 (% 
4 2 (10) 
4 (20) 
2 (10) 
3 (15) 
3 (15) 
2 (10) 
2 (10) 
3 (15) 
2 (10) 
 7 (88) 
8 (100) 
6 (75) 
6 (75) 
7 (88) 
7 (88) 
6 (75) 
7 (88) 
4 (50) 
<0.001 7 (35) 
6 (30) 
10 (50) 
14 (70) 
13 (65) 
12 (60) 
15 (75) 
15 (75) 
13 (65) 
 8 (100) 
8 (100) 
7 (88) 
8 (100) 
8 (100) 
8 (100) 
8 (100) 
8 (100) 
8 (100) 
5  <0.001  
6B  0.002  
7F  <0.001  
9V  0.001  
14  <0.001  
18C  0.002  
19F  0.001  
23F  0.038  
aDefined as an at least 2-fold increase and a post-vaccination concentration of at least 0.35 μg/ml 
bFisher´s exact test 
 
 
